Page last updated: 2024-10-27

fluoxetine and Lipidoses

fluoxetine has been researched along with Lipidoses in 4 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Lipidoses: Conditions characterized by abnormal lipid deposition due to disturbance in lipid metabolism, such as hereditary diseases involving lysosomal enzymes required for lipid breakdown. They are classified either by the enzyme defect or by the type of lipid involved.

Research Excerpts

ExcerptRelevanceReference
" The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated."5.27Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987)
"The side effect profile and safety of fluoxetine are reviewed."3.75The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985)
"Phospholipidosis (PLD) is a lysosomal storage disorder induced by compounds, notably cationic amphiphilic drugs, which although reversible interferes with cellular phospholipids."1.38In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets. ( Atzpodien, EA; Csato, M; Doessegger, L; Fischer, H; Lenz, B; Schmitt, G; Singer, T, 2012)
"Phospholipidosis is an adverse effect caused by numerous cationic amphiphilic drugs and can affect many cell types."1.36Predicting phospholipidosis using machine learning. ( Glen, RC; Lowe, R; Mitchell, JB, 2010)
" The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated."1.27Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987)

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19902 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Lowe, R1
Glen, RC1
Mitchell, JB1
Fischer, H1
Atzpodien, EA1
Csato, M1
Doessegger, L1
Lenz, B1
Schmitt, G1
Singer, T1
Wernicke, JF1
Zerbe, RL1

Reviews

1 review available for fluoxetine and Lipidoses

ArticleYear
The side effect profile and safety of fluoxetine.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical

1985

Trials

1 trial available for fluoxetine and Lipidoses

ArticleYear
The side effect profile and safety of fluoxetine.
    The Journal of clinical psychiatry, 1985, Volume: 46, Issue:3 Pt 2

    Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical

1985

Other Studies

3 other studies available for fluoxetine and Lipidoses

ArticleYear
Predicting phospholipidosis using machine learning.
    Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5

    Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Bio

2010
In silico assay for assessing phospholipidosis potential of small druglike molecules: training, validation, and refinement using several data sets.
    Journal of medicinal chemistry, 2012, Jan-12, Volume: 55, Issue:1

    Topics: Animals; Cattle; Cells, Cultured; Computer Simulation; Cornea; Drug-Related Side Effects and Adverse

2012
Safety of fluoxetine in the treatment of obesity.
    International journal of obesity, 1987, Volume: 11 Suppl 3

    Topics: Drug Interactions; Fluoxetine; Heart; Humans; Lipidoses; Liver; Obesity; Phospholipids; Propylamines

1987